Acute myeloid leukemia with t (8;21) translocation diagnosed at 21 weeks of gestation resulting in full-term delivery without chemotherapy

DOI Web Site PubMed
  • NORIHAMA Yuka
    Department of Obstetrics and Gynecology, Japanese Red Cross Medical Center
  • NOMURA Moe
    Department of Hematology, Japanese Red Cross Medical Center
  • ODA Yuki
    Department of Hematology, Japanese Red Cross Medical Center
  • KASUYA Yuki
    Department of Hematology, Japanese Red Cross Medical Center
  • TAKEI Tomomi
    Department of Hematology, Japanese Red Cross Medical Center
  • SATO Kota
    Department of Hematology, Japanese Red Cross Medical Center
  • OGURA Mizuki
    Department of Hematology, Japanese Red Cross Medical Center
  • KIKUCHI Taku
    Department of Hematology, Japanese Red Cross Medical Center
  • ABE Yu
    Department of Hematology, Japanese Red Cross Medical Center
  • ISHIDA Tadao
    Department of Hematology, Japanese Red Cross Medical Center
  • KASAI Yasuyo
    Department of Obstetrics and Gynecology, Japanese Red Cross Medical Center
  • TSUKADA Nobuhiro
    Department of Hematology, Japanese Red Cross Medical Center

Bibliographic Information

Other Title
  • 妊娠21週で診断され無治療で正期産に至ったt（8;21）転座を伴う急性骨髄性白血病
  • ニンシン 21シュウ デ シンダン サレ ムチリョウ デ セイキサン ニ イタッタ t(8;21)テンザ オ トモナウ キュウセイ コツズイセイ ハッケツビョウ

Search this article

Abstract

<p>A 28-year-old female was diagnosed with acute myeloid leukemia (AML) due to t (8;21) (q22;q22.1); RUNX1-RUNX1T1 at 21 weeks of gestation. Because no adverse prognostic genetic mutations were discovered, we decided to continue the pregnancy without chemotherapy for as long as possible. After careful monitoring with blood tests every two weeks, the disease did not progress until full-term, and a cesarean section was performed at 39 weeks of gestation. About two months after delivery, blasts in the peripheral blood increased to 46.5%, and myeloblasts in the bone marrow increased to 21.2%. The patient received idarubicin and cytarabine induction therapy, followed by three cycles of high-dose cytarabine consolidation therapy, and complete remission was maintained. Here we report a rare case who could avoid chemotherapy until full-term labor without progression of AML.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 64 (8), 731-734, 2023

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top